Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Barr Website

Frederic G. Barr, M.D., Ph.D.

Selected Publications

1)  Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Cancer Discov. 4: 216-31, 2014.
[Journal]
2)  Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM.
Myogenin, AP2ß, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children"s Oncology Group.
Am. J. Surg. Pathol. 38: 654-9, 2014.
[Journal]
3)  Parham DM, Barr FG.
Classification of rhabdomyosarcoma and its molecular basis.
Adv Anat Pathol. 20: 387-97, 2013.
[Journal]
4)  Duan F, Smith LM, Gustafson DM, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG.
Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: A report from the Children's Oncology Group.
Genes Chromosomes Cancer. 51: 662-74, 2012.
[Journal]
5)  Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18: 748-57, 2012.
[Journal]
6)  Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG.
Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
Clin. Cancer Res. 17: 1463-73, 2011.
[Journal]
7)  Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG.
Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 57: 930-8, 2011.
[Journal]
8)  Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, Lim D, Marchetti A, Viale A, Pirun M, Socci ND, Qin LX, Sciot R, Bridge J, Singer S, Meyers P, Wexler LH, Barr FG, Dogan S, Fletcher JA, Reis-Filho JS, Ladanyi M.
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
Nat. Genet. 46: 595-600, 2014.
[Journal]
9)  Sadri N, Barroeta J, Pack SD, Abdullaev Z, Chatterjee B, Puthiyaveettil R, Brooks JS, Barr FG, Zhang PJ.
Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion.
Virchows Arch. 2014.
[Journal]
10)  Parham DM, Barr FG.
Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F, eds.
Alveolar rhabdomyosarcoma. In: WHO Classification of Tumours of Soft Tissue and Bone.
Lyon: IARC Press; 2013. p. 130-132 [Book Chapter]
Click Here to View Expanded Bibliography.

This page was last updated on 7/29/2014.